BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy
"Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community."
EB Simplex is a rare, inherited skin disorder that causes painful blistering due to fragile skin, affecting an estimated 30,000 to 50,000 individuals worldwide. With current treatment limited to wound care and infection control, patients and families face a lifelong battle without disease-modifying options. TolaSure, developed by BioMendics, aims to change that reality by targeting the mutant keratins that underlie skin fragility, offering a novel mechanism to reduce blister burden and improve quality of life.
The TAMES-02 trial builds on the success of the earlier TAMES-01 study, which demonstrated TolaSure's safety and efficacy in adult patients.
Dr. Joyce Teng, Principal Investigator at Stanford University, shared:
'Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community. Clinical research in rare skin diseases requires collaboration with companies like BioMendics and patient advocacy groups like debra of America to accelerate progress toward transformative therapies. Our shared goal is to bring hope and healing to families who have had so few options for so long.'
TAMES-02 is being conducted in partnership with Stanford University School of Medicine and Northwestern University Feinberg School of Medicine—two globally recognized leaders in dermatology research. The trial will evaluate TolaSure in patients aged 4 and older and includes a 2-month double-blind, placebo-controlled phase, followed by a 2-month open-label phase where all participants receive TolaSure, and a 6-month follow-up. Importantly, the trial allows patients to treat plantar (foot) blistering—a major source of pain and disability for those living with EB Simplex.
Dr. Amy Paller, Principal Investigator at Northwestern University, added:
'TAMES-02 is a vital next step. The collaboration with BioMendics and Stanford enables us to rigorously evaluate this therapy and, hopefully, bring real progress to patients who have had limited options for far too long.'
'We're really excited to be able to cover travel cost to bring patients in from all over the United States and internationally,' said Dr. Aleesha McCormick Senior clinical research scientist at BioMendics. ' EB Simplex patients don't all live close to an Academic Medical Center like Stanford and Northwestern and our goal is to help as many patients be able to participate in the study as possible. Our study design also lets us recruit slightly less severe patients that may not have flared enough to be eligible for other clinical studies. '
'Our mission is to bring meaningful therapies to patients living with rare diseases like EB Simplex—conditions that have been overlooked for too long,' said Dr. Karen M. McGuire, CEO and Founder of BioMendics. 'With TolaSure, we're targeting the root cause of blistering by reinforcing fragile keratinocytes. The TAMES-02 trial is a critical step toward proving safety and efficacy. If successful, we'll seek strategic partnerships to help accelerate development and deliver this treatment to patients as quickly as possible. We also see strong potential for TolaSure in other rare keratin disorders such as pachyonychia congenita and epidermolytic ichthyosis.'
TAMES-02 reflects BioMendics' ongoing commitment to developing innovative, targeted treatments for rare skin disorders and is currently open for patient enrollment.
About BioMendics:
For more information about BioMendics please visit our website (www.biomendics.com). BioMendics is proud to be a REDIzone company at Northeast Ohio Medical University (NEOMED). The REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) supports local life science and biomedical entrepreneurs by providing access to NEOMED's resources, expertise, and connections to the region's innovation ecosystem. This partnership has been instrumental in advancing TolaSure from research to clinical development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
2 hours ago
- Fast Company
How scientists caught AI writing their colleagues' papers
A massive new study scanned more than one million scientific papers for signs of AI and the results were overwhelming: AI is everywhere. The study, published this week in Nature Human Behaviour, analyzed preprints and papers published from 2020 to 2024 by searching for some of the signature traces that AI-generated tools leave behind. While some authors deceptively using AI might slip up and leave obvious clues in the text – chunks of a prompt or conspicuous phrases like 'regenerate response,' for instance – they have become savvier and more subtle over time. In the study, the researchers created a statistical model of word frequency using snippets of abstracts and introductions written before the advent of ChatGPT and then fed them through a large language model. By comparing the texts, the researchers found hidden patterns in the AI-written text to look for, including a high frequency of specific words like 'pivotal,' 'intricate,' and 'showcase,' which aren't common in human-authored science writing. Some research areas rely on AI, others don't The authors found widespread use of large language models across research topics, but some fields appeared to rely on AI much more heavily than others. In computer science abstracts, an estimated 22.5% of sentences showed evidence of AI usage, compared to 9.8% for physics papers and 7.8% for mathematics. 'We see the biggest increases in the areas that are actually closest to AI,' co-author and Stanford computational biologist James Zou said. Shorter papers and papers in crowded fields of research showed more signs that they were partially written by AI. Many academic journals have added rules requiring authors to disclose the use of generative AI tools like ChatGPT. Prominent journals including Science and Nature explicitly state that AI cannot author a paper, but AI can be used for more minor processes like copyediting and grammar. For some journals, the AI prompts used in crafting a paper must be detailed in depth in a paper's methods section. If the threat of introducing hallucinations into a paper isn't enough of a deterrent, authors trying to sneakily use AI run the risk of getting called out by running databases dedicated to documenting AI transgressions in research. 'Machines play an important role, but as tools for the people posing the hypotheses, designing the experiments, and making sense of the results,' Science Editor-in-Chief wrote in a letter on AI use in research. 'Ultimately the product must come from—and be expressed by—the wonderful computer in our heads.'
Yahoo
6 hours ago
- Yahoo
SpaceX rocket to launch Amazon Kuiper satellites from Florida on Saturday
The Brief SpaceX is set to launch the KF-02 mission on Saturday from Cape Canaveral, carrying Amazon's Kuiper internet satellites into low-Earth orbit. The Falcon 9 rocket is scheduled to lift off during a 27-minute window starting at 9:18 a.m. ET, with a planned landing on the droneship A Shortfall of Gravitas. The KF-02 mission is part of Amazon's effort to build a global broadband network, aiming to deliver fast, reliable internet worldwide. CAPE CANAVERAL, Fla. - SpaceX is preparing to launch the KF-02 mission on Saturday morning, sending Amazon's Kuiper satellites into space from Florida. The launch, which was originally set for Thursday, was pushed back to Friday to allow for more vehicle checks. On Friday, SpaceX postponed the launch again. What they're saying "Now targeting Saturday, August 9 for launch of the KF-02 mission from pad 40 in Florida," SpaceX wrote on X. "Teams are keeping an eye on weather, which is currently 35% favorable for liftoff." When is the rocket launch? What we know A Falcon 9 rocket is set to blast off from Space Launch Complex 40 (SLC-40) at the Cape Canaveral Space Force Station, carrying out the KF-02 mission. SpaceX is now targeting a 27-minute launch window that opens at 9:18 a.m. ET on Aug. 9. CLICK TO DOWNLOAD THE FOX LOCAL APP After stage separation, the Falcon 9 will land on A Shortfall of Gravitas droneship, which will be stationed in the Atlantic Ocean. What is the KF-02 mission? The backstory The Kuiper Falcon 2 (KF-02) is Amazon's low-Earth orbit satellite broadband network. The goal is to provide fast, reliable internet to customers around the world. By the numbers This launch will mark the first flight for the first stage booster supporting this mission. How to watch and stream the rocket launch live FOX 35 News will stream the launch live in the video player at the top of this page. You can also stream the launch onFOX Local. Many launches are also visible from various locations in Florida, especially along the coast, including public viewing areas near Cape Canaveral or Kennedy Space Center, depending on the mission. SIGN-UP FOR FOX 35'S BREAKING NEWS, DAILY NEWS NEWSLETTERS The Source This story was written based on information shared on SpaceX's website on August 8, 2025. Solve the daily Crossword
Business Wire
6 hours ago
- Business Wire
BerryDunn Showcases Thought Leadership and Expertise at 2025 MESC Conference
PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service accounting, tax, and consulting firm, will return for the 25th year to the Medicaid Enterprise Systems Conference (MESC), taking place August 11 – 14 in Milwaukee, WI. The firm is a leading voice in Medicaid and other Health and Human Services (HHS) policy, program excellence, and healthcare data analytics, with decades of hands-on experience supporting states and territories. The MESC brings together territorial, state, federal, and private-sector leaders to discuss and collaborate on Medicaid and other HHS systems and the policies that affect them. Hot topics at MESC 2025 include systems optimization, healthcare IT strategy, and a strong emphasis on modernization, interoperability, and health equity. 'The urgency for the healthcare community to prioritize the well-being of those they serve—while modernizing systems, ensuring compliance, and driving innovation—has never been greater,' says Zachary Rioux, Principal at BerryDunn. 'Our team is deeply committed to helping clients build future-ready solutions that are both strategic and sustainable. We've supported agencies in preparing for and responding to major federal legislation like the One Big Beautiful Bill Act (OBBBA), and we continue to guide clients through the evolving policy landscape.' BerryDunn's involvement with industry associations, governance boards, and conferences enables the consulting team to anticipate and help clients respond to developments like the recent State Health Officials (SHO) letter #25003 and upcoming changes to the Medicaid Information Technology Architecture (MITA). MESC is a powerful gathering of ideas, experience, and purpose—and BerryDunn is proud to be part of a community that's driving meaningful change in healthcare. Several BerryDunn professionals will play a leading role in this year's conference presentations, including: Alexandra Nardo and Robert Morey will speak during a session titled 'Building the Foundation for AI: Puerto Rico's AI Readiness Roadmap.' The session explores the Puerto Rico Medicaid Program's assessment, planning process, and roadmap in support of the agency's AI considerations. Delivering purposeful results through partnership, Amber Davis, a Manager in BerryDunn's Medicaid Practice Group, will moderate a session on 'Advancing Medicaid Innovation through the CMS Leverage & Reuse Initiative.' This session will explore how states and territories are collaborating to drive efficiency, reduce costs, and accelerate innovation in Medicaid technology. Partnering with CMS and the leadership team at the Puerto Rico Medicaid Program (PRMP), Nikki Welch, Manager at BerryDunn, will present 'Leveraging Organizational Change Management (OCM) Maturity Results to Enhance Medicaid Outcomes.' This session highlights PRMP's journey to integrate OCM practices across Medicaid Enterprise Systems (MES) and how the use of BerryDunn's OCM Maturity Assessment framework has provided measurable insights that directly support program success. 'Our team members gain valuable perspective by being actively engaged in Medicaid IT and policy planning at the national and state levels,' says Ed Daranyi, BerryDunn Principal and leader of the firm's Medicaid Practice Group. 'We provide those insights and deep industry knowledge to clients across the country, supporting innovation in client solutions.' As BerryDunn celebrates 25 years at MESC, the firm remains committed to helping agencies navigate complexity with clarity, purpose, and innovation. With deep expertise in policy, technology, and program excellence, BerryDunn continues to lead with insight and impact. About BerryDunn BerryDunn is the brand name under which Berry, Dunn, McNeil & Parker, LLC and BDMP Assurance, LLP, independently owned entities, provide services. Since 1974, BerryDunn has helped businesses, nonprofits, and government agencies throughout the US and its territories solve their greatest challenges. The firm's tax, advisory, and consulting services are provided by Berry, Dunn, McNeil & Parker, LLC, and its attest services are provided by BDMP Assurance, LLP, a licensed CPA firm. BerryDunn is a client-centered, people-first professional services firm with a mission to empower the meaningful growth of our people, clients, and communities. Led by CEO Sarah Belliveau, the firm has been recognized for its efforts in creating a diverse and inclusive workplace culture, and for its focus on learning, development, and well-being. Learn more at
